AC5 is a proprietary self-assembling, synthetic wound care product that provides multi-modal support to clinicians and has utility across all phases of wound healing. AC5 is indicated for the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds.
The following clinical cases, which examine the use of AC5 in patients with acute, chronic, and challenging wounds, will be presented.
- The Use of a Synthetic Self-Assembling Peptide Matrix in a Limb Salvage Setting
Christopher Gauland , DPM –East Carolina University ,Brody School of Medicine ,Greenville, NC
Poster Number: CS-046
Honor: Highest Scoring Poster Abstract in Case Series/Study Category - Treatment of Hard to Heal Acute and Chronic Wounds with a Synthetic Self-Assembling Peptide Matrix
Terry Treadwell , MD, FACS, FAAWC and Lyudmila Nikolaychook, DO –Institute for Advanced Wound Care ,Montgomery, AL
Poster Number: CS-140
In addition to the Poster Presentations by wound care experts Dr.
Representatives from Arch will be available at SAWC booth #534 in the exhibit hall for inquiries.
Over 1,000 wound care specialists—physicians, nurses, physical therapists, researchers, scientists, and podiatrists—are registered to attend SAWC Fall. The agenda is focused on sharing best practices to improve patient outcomes. Registration for the symposium can be found at https://www.sawcfall.com/.
About
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our ability to recruit additional field sales representatives and their effectiveness, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to satisfy our existing obligations and continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to obtain the inclusion of our AC5® Advanced Wound System on targeted federal supply schedules, our ability to develop and commercialize products based on our technology platform, and market conditions, and our ability to establish additional commercialization partnerships and build a critical mass of field sales representatives. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the
1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.
2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of
Contact:
ARTH Investor Relations
Toll Free: +1.855.340.ARTH (2784) (US and
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com
or
Chief Financial Officer
Phone: 617.431.2333
Email: mabrams@archtherapeutics.com
Source:
2022 GlobeNewswire, Inc., source